Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) November 10, 2022
H.C. Wainwright 24th Annual Global Investment Conference, September 12 – 14, 2022 Webcast – Replay September 15, 2022
ESMO: B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells September 12, 2022
AACR: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas April 9, 2022
EBMT: A Tri-specific Killer Engager (TriKE®) against B7-H3 enhances NK cell mediated killing of multiple myeloma March 22, 2022
ESMO Targeted Anticancer Therapies Congress: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE®) March 9, 2022
